Thompson v. Raiford Complaint in Intervention
Public Court Documents
October 21, 1992

Cite this item
-
Brief Collection, LDF Court Filings. Thompson v. Raiford Complaint in Intervention, 1992. 00b8b204-c69a-ee11-be37-00224827e97b. LDF Archives, Thurgood Marshall Institute. https://ldfrecollection.org/archives/archives-search/archives-item/e5814449-a869-46bb-acec-37531e53b176/thompson-v-raiford-complaint-in-intervention. Accessed May 04, 2025.
Copied!
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF TEXAS DALLAS DIVISION LOIS THOMPSON on behalf of and as next CASE NO. 3-92 CV 1539-R friend to TAYLOR KEONDRA DIXON, ZACHERY X. WILLIAMS, CALVIN A. THOMPSON and PRENTISS LAVELL MULLINS, Plaintiffs, Civil Action PEOPLE UNITED FOR A BETTER OAKLAND, on behalf of its members; DENVER ACTION FOR A BETTER COMMUNITY, on behalf of its members; NEW YORK CITY COALITION TO END LEAD POISONING, on behalf of its members; ROBIN GOURLEY on behalf of and as next friend to BRYAN ALAN GOURLEY, WESLEY KYLE GOURLEY, BRIDGET MICHELLE GOURLEY, LINDA DANIELLE GOURLEY and BETSEY IRENE GOURLEY; TEARRAH ROBERSON on behalf of and as guardian ad litem to JUAN WILKINS; and MARY MARIE ROBERSON on behalf of and as guardian ad litem to ASHARD MOORE, JASON ROLLINS, ASHEA ROBERSON, and NASHEIKA ROBERSON, Plaintiff-Intervenors, Class Action [PROPOSED] COMPLAINT IN INTERVENTION BURTON F. RAIFORD, in his capacity as Commissioner of the Texas Department of Human Services, The UNITED STATES OF AMERICA, Defendants, LOUIS W. SULLIVAN, in his capacity as Secretary of the United States Department of Health and Human Services, Additional Defendant. Introduction 1. Plaintiff-intervenors People United for a Better Oakland, Denver Action for a Better Community, and New York City Coalition to End Lead Poisoning, whose members include parents and guardians of Medicaid-eligible children in the States of California, Colorado, and New York, as well as Medicaid-eligible children from North Carolina submit this complaint in intervention to join the original class action lawsuit against federal defendants filed by Medicaid-eligible children residing in Texas. Plaintiff-intervenors, Medicaid-eligible individuals and organizations whose members include parents of Medicaid- eligible children, are denied or are threatened with the denial by federal defendants of "screening services . . . which shall at a minimum include laboratory tests (including lead blood level assessment appropriate for age and risk factors)" for lead poisoning required by the Early and Periodic Screening, Diagnostic and Treatment (hereinafter "EPSDT") program of the Medicaid Act. 42 U.S.C. §§ 1396d(a)(4)(B) and 1396d(r). 2. In particular, federal defendants have refused to require the use of lead blood level tests to screen for lead poisoning by States participating in the EPSDT Medicaid program, notwithstanding the Medicaid Act and even though the lead blood level test provides definitive information concerning the extent to which a child has been exposed recently to lead. Rather, they permit the States to use an inadequate screening procedure, the erythrocyte protoporphyrin (hereinafter "EP") test, which does not measure lead blood levels as required by the statute and which provides, at best, marginal information for about one out of seven or eight children indicating that a child may be lead poisoned. The federal defendants’ position was confirmed by their issuance of an EPSDT Medicaid guidance on September 16, 1992 permitting the use of the EP test to screen for lead poisoning. As a result, thousands of lead-poisoned, Medicaid-eligible children throughout the nation remain unidentified and, therefore, untreated notwithstanding the clear mandate of the Medicaid Act. 3. Defendant United States of America, through additional defendant Louis W. Sullivan, the Secretary of the Department of Health and Human Services (hereinafter "HHS"), has declared that lead poisoning is the number one environmental health problem for children 2 in the United States today. The incidence of lead poisoning is two to three times greater for poor, Medicaid-eligible children than for better off children. Fully 2/3 of African- American inner city children, for instance, are estimated to have been poisoned by lead. 4. Exposure to lead in the environment causes a wide range of health problems. Young children and fetuses are especially sensitive to lead because their nervous systems are still developing and many of lead’s effects are observed in children at lower concentrations than in adults. Children exposed to lead may suffer from impairment of mental and physical development, anemia, hearing problems, and decreased levels of Vitamin D. Children exposed to lead are six times more likely to have a reading disability and seven times more likely not to graduate from high school than their peers. 5. Lead poisoning, for the most part, is asymptomatic: early symptoms are mild and often mimic other common childhood disorders. As a result, the vast majority of pending cases go undiagnosed and untreated. 6. The "Strategic Plan For the Elimination of Childhood Lead Poisoning" (hereinafter "Strategic Plan") issued by defendant Sullivan in February 1991, on behalf of HHS, states at pp. iii and xi: Childhood lead poisoning has already affected millions of children, and it could affect millions more. Its impact on children is real, however silently it damages their brains and limits their abilities. * * * Today in the United States, millions of children from all geographic areas and socioeconomic strata have lead levels high enough to cause adverse health effects. Poor, minority children in the inner cities, who are already disadvantaged by inadequate nutrition and other factors, are particularly vulnerable to this 3 disease. The Strategic Plan also notes that "many States do not conduct much screening or do not pay for environmental investigations for poisoned children" under their Medicaid EPSDT programs. Id. at p. 18. 7. The Agency for Toxic Substances and Disease Registry, a subdivision of HHS, has reported that more than three million children — one in six — have levels of lead in their blood high enough to cause significant impairment of their neurological development. 8. The Centers for Disease Control, the subdivision of HHS which provides guidance on medical and public health questions, in 1991 issued a statement entitled "Preventing Lead Poisoning in Young Children," finding that: Although all children are at risk, poor and minority children are disproportionately affected. Lead exposure is at once a by-product of poverty and contributes to the cycle that perpetuates and deepens the state of being poor. Id. at 12. 9. The Centers for Disease Control also found the harmful effects of lead poisoning at blood lead levels at least as low as ten micrograms per deciliter (/Ltg/dL). The previous threshold had been 25 /xg/dL. As a result, the Centers for Disease Control stated that "the screening test of choice is now lead blood measurement" because "the erythrocyte protoporphyrin level [which is measured by the EP test] is not sensitive enough to identify children with elevated lead blood levels below 25 /zg/dL." Id at 2. The Centers for Disease Control also dictated the following treatment protocol: Community prevention activities should be triggered by lead blood levels > 10 /ug/dL. Medical evaluation and environmental investigation and remediation should be done for all children with lead blood levels > 20 /xg/dL. All children with lead blood 4 levels > 15 ^ug/dL should receive individual case management, including nutritional and educational interventions and more frequent screening. Furthermore, depending on the availability of resources, environmental investigation (including a home inspection) and remediation should be done for children with lead blood levels of 15-19 /xg/dL, if such levels persist. Id. at 2. Jurisdiction and Venue 10. The underlying civil action is authorized by 42 U.S.C. § 1983 to redress the deprivation under color of state law of rights, privileges, and immunities guaranteed by the Constitution of the United States or by act of Congress. This Court has jurisdiction pursuant to 28 U.S.C. §§ 1331 and 1343 (3) and (4). 11. This civil action is authorized by 5 U.S.C. § 701 et seq. and 28 U.S.C. §§ 1331 and 1361 to redress the deprivation by federal agency action of rights, privileges and immunities guaranteed by the Constitution of the United States or by acts of Congress, and to compel the individual federal defendant to perform his duty under the Medicaid Act. 12. This Court has authority to grant declaratory relief pursuant to 5 U.S.C. § 702, 28 U.S.C. § 2201, and Fed.R.Civ. P. 57, to grant injunctive relief pursuant to 5 U.S.C. § 703, 28 U.S.C. § 2202, and Fed.R.Civ. P. 65, and to issue relief in the nature of mandamus pursuant to 28 U.S.C. § 1361. 13. The original plaintiffs reside in the Northern District of Texas and defendants named herein maintain offices in this District or are responsible for enforcing the laws relevant to this litigation in this District. 14. Intervention as of right by plaintiff-intervenors is appropriate pursuant to Fed.R.Civ.P. 24(a)(2) and permissive intervention by plaintiff-intervenors is appropriate under Fed.R.Civ.P. 24(b)(2). 5 Prior Demand 15. Plaintiff-intervenors’ counsel requested that federal defendants comply with plaintiff-intervenors’ requests for relief, but defendant Sullivan declined. See attachments A and B. Parties 16. Plaintiff-intervenor People United for a Better Oakland (hereinafter "PUEBLO") is a multi-racial unincorporated organization whose membership is comprised primarily of parents and guardians of Medicaid-eligible children in the State of California. One of PUEBLO’s purposes is to advocate adequate screening for lead poisoning. Pursuant to a stipulation for settlement entered in Erika and Jalisa Matthews and PUEBLO v. Molly Coye, N.D. Cal. 90-3620 EFL (approved October 17, 1991), Medicaid-eligible children of PUEBLO’s members and other California residents have been provided screening for lead poisoning using a lead blood level assessment. As a result of federal defendants’ refusal to require lead blood level assessment testing under the EPSDT program, the Medicaid-eligible children of PUEBLO’s members are threatened with the denial of lead blood level screening for lead poisoning notwithstanding the Matthews settlement. 17. Plaintiff-intervenor Denver Action for a Better Community (hereinafter "ABC") is a multi-racial unincorporated organization whose membership is comprised primarily of parents and guardians of Medicaid-eligible children living in the State of Colorado who have been denied lead blood level assessment tests to screen for lead poisoning. One of ABC’s purposes is to advocate adequate screening for lead poisoning. 6 18. Plaintiff-intervenor New York City Coalition to End Lead Poisoning (hereinafter "NYCCELP") is an unincorporated membership organization whose members include parents and guardians of Medicaid-eligible children throughout New York City who have been and are being threatened with the denial of lead blood assessments to screen for lead poisoning. One of NYCCELP’s purposes is to educate and advocate for the families of Medicaid-eligible children to obtain proper lead poisoning screening through New York State’s Medicaid program. For almost eight years NYCCELP has been litigating this issue. Almost six years ago, before Congress enacted 42 U.S.C. § 1396d(r)(l), NYCCELP obtained a court ruling requiring appropriate and sufficient lead poisoning screening under the federal EPSDT program in New York City. N.Y.C. Coalition to End Lead Poisoning v. Koch. 524 N.Y.S.2d 314, 318-19 (Sup. Ct. 1987), ajfd, 526 N.Y.S.2d 918 (1st Dep’t 1988). NYCCELP has now moved for a permanent injunction requiring New York State and New York City to provide proper, accurate lead blood tests under the Medicaid program, based on New York’s failure to follow federal law. Id., Index No. 42780/85, Plaintiffs’ Motion for Specific Enforcement (filed May 18, 1992; argued Oct. 19, 1992). Federal defendants’ policy will thwart the progress NYCCELP’s members have made toward adequate lead blood level screening. 19. Plaintiff-intervenors Bryan Alan Gourley, age seven, Wesley Kyle Gourley, age six, Bridget Michelle Gourley, age four, and twins Linda Danielle and Betsey Irene Gourley, age three, are Caucasian children eligible for Medicaid benefits who reside in North Carolina. They intervene through their mother, plaintiff-intervenor Robin Gourley. Because of their Medicaid eligibility, the Gourley children are entitled to lead blood level tests for lead poisoning through the EPSDT program, but they have not received any. 20. Plaintiff-intervenors Juan Wilkins, 19 months old, Ashard Moore, six years old, Jason Rollins, 11 years old, Ashea Roberson, 12 years old, and Nasheika Roberson, 16 years 7 old, are African American North Carolina residents eligible for Medicaid services. Plaintiff- intervenor Juan intervenes through his guardian ad litem Tearrah Roberson, and the remaining children intervene through their guardian ad litem Mary Marie Roberson. In 1992, plaintiff-intervenors’ public housing unit was found to contain lead paint on the window sills and doorways. Plaintiff-intervenors Ashard, Jason, Ashea and Nasheika, sought lead blood tests at the local health department and were administered the EP test. Plaintiff- intervenors were not given readings of their lead blood levels but Ashard, Ashea, and Nasheika were told that they are anemic — a sign that they might be lead poisoned. Plaintiff-intervenor Juan has not been offered a lead blood test. 21. Defendant United States of America administers the EPSDT program through HHS the federal agency charged with the administration of the program under the Medicaid Act. Additional defendant Louis W. Sullivan, the Secretary of HHS, is sued in his official capacity. Under defendant Sullivan’s supervision, HHS has failed to implement lead blood level assessment testing for Medicaid-eligible children in violation of the Medicaid Act. The joinder of defendant Sullivan is proper under Fed.R.Civ.P.19(a) and 20(a). Class Action Allegations 22. Plaintiff-intervenors represent a class of all Medicaid-eligible children presently residing in the United States. 23. As of 1989, there were 10 million Medicaid-eligible children residing in the United States. The class of all these persons is so numerous that their joinder is impracticable. 24. Plaintiff-intervenors’ allegations that defendants have violated the Medicaid Act involve questions of law or fact common to the class. 25. The tactual and legal assertions upon which plaintiffs-intervenors’ claims are based are identical to the basic factual and legal claims asserted on behalf of the class. 26. The claims of plaintiff-intervenors and organizational plaintiff-intervenors’ 8 members’ Medicaid-eligible children are typical of the claims of the class. 27. There is no conflict between the plaintiff-intervenors and the plaintiff class. Plaintiff-intervenor individuals and organizations seek the same injunctive relief on their own behalves or on behalf of their members as is sought on behalf of the class. Plaintiff- intervenors are represented by competent counsel. Plaintiff-intervenors therefore will adequately represent the interests of the plaintiff class. 28. Defendants have acted or refused to act on grounds generally applicable to the class thus making appropriate final injunctive relief or corresponding declaratory relief with respect to the class as a whole. First Claim for Relief—Violation of Medicaid Act 29. Plaintiff-intervenors incorporate by reference paragraphs 1-28. 30. The Medicaid program was established in 1965 by Title XIX of the Social Security Act, 42 U.S.C. § 1396 et seq., as a cooperative federal-state medical assistance program designated to furnish medical assistance to certain poor people. The program is administered by the States, subject to mandatory federal statutory requirements. While participation in the Medicaid program is voluntary, States that choose to participate must fulfill all requirements imposed by the Medicaid Act, including the requirements of the EPSDT program. 42 U.S.C. §§ 1396d(a)(4)(B) and 1396d(r). 31. The Medicaid Act requires "screening services . . . which shall at a minimum include laboratory tests (including lead blood level assessment appropriate for age and risk factors)." 42 U.S.C. § 1396d(r)(l). 32. Defendant Sullivan implements the requirements of the Medicaid Act applicable to the States through regulations and guidelines, notably the "State Medicaid Manual" (hereinafter "Manual") of HHS Health Care Finance Administration. 33. Recent amendments to the Manual, which became effective on September 19, 1992, permit the continued use of the EP test ("States continue to have the option to use the 9 EP test as the initial screening blood test."). The Manual permits the use of the EP test although it acknowledges that lead poisoning is harmful at levels at least as low as ten /zg/dL and that ”[t]he erythrocyte protoporphyrin (EP) test is not sensitive for lead blood levels below 25 /zg/dL." 34. Defendant Sullivan’s 1991 "Strategic Plan" at p. 40, stated "At present it is much cheaper and easier to perform an EP test than a blood lead measurement; however, the EP test is not a useful screening test for blood lead levels below 25 /zg/dL." The Strategic Plan correctly forecast that the Centers for Disease Control would lower the level of lead blood that would be harmful below 25 jzg/dL in 1991 and stated that: This change will mean that blood lead measurements must be used for childhood lead screening instead of EP measurements. Id. at 23 (Emphasis added). 35. Defendant Sullivan had earlier issued a report entitled "The Nature and Extent of Lead Poisoning in Children in the United States: A Report to Congress," in 1988, which analyzed the existing research on the reliability of the EP test as a screening test for lead poisoning and concluded, at p. II-9: "[R]eliance on EP level for initial screening can result in a significant incidence of false negatives or failures to detect toxic Pb-B [lead blood] levels." 36. The actions of federal defendants refusing to require use of lead blood level assessment tests and permitting the States to use the EP test to screen for lead poisoning under the EPSDT program violate the Medicaid Act and are substantially unjustified. 37. By refusing to require the States to use a lead blood level assessment test to screen for lead poisoning under the EPSDT Medicaid program and permitting the States to use the EP test, federal defendants have deprived plaintiffs-intervenors of rights, privileges, and immunities guaranteed by the Constitution and laws of the United States. Second Claim for Relief — Mandamus 38. Plaintiff-intervenors incorporate by reference paragraphs 1 through 37. 10 39. By tailing to require the States to use a lead blood level assessment test to screen for lead poisoning under the EPSDT Medicaid program and permitting the States to use the EP test, federal defendants have failed to perform a clear mandatory duty required by a specific provision of the Medicaid Act, 42 U.S.C. §§ 1396d(a)(4)(B) and 1396d(r)(l). 40. Plaintiff-intervenors are therefore entitled to an order compelling performance of the mandatory duty to require use of lead blood level assessment tests to screen for lead poisoning under the EPSDT Medicaid program. Third Claim for Relief — Injunction 41. Plaintiff-intervenors incorporate by reference paragraphs 1 through 40. 42. Unless restrained by the Court, federal defendants will continue to deny or threaten to deny plaintiff-intervenors lead blood level assessment tests required by the Medicaid Act, 42 U.S.C. §§ 1396d(a)(4)(B) and 1396d(r)(l), to screen for lead poisoning. 43. Plaintiff-intervenors have no plain, speedy or adequate remedy at law. The refusal of federal defendants to require the States to use lead blood level assessments tests to screen for lead poisoning therefore should be enjoined. Fourth Claim for Relief — Declaration 44. Plaintiff-intervenors incorporate by reference paragraphs 1 through 43. 45. There is a dispute between plaintiff-intervenors and federal defendants under the Medicaid Act in that plaintiff-intervenors claim and contend that the federal defendants’ conduct described above violates the Medicaid Act and Mandamus Act and in that plaintiff- intervenors are informed and believe and thereupon allege that federal defendants contend in all respects to the contrary. 46. A declaration of the correct interpretation of the Medicaid Act therefore is necessary and appropriate to determine the respective rights and duties of the parties. 11 Prayer for Relief 47. Plaintiff-intervenors seek the following relief against federal defendants Louis W. Sullivan and United States of America: a. a preliminary and permanent injunction enjoining federal defendants from giving effect to the State Medicaid Manual and revisions that permit the States to use the EP test as a screening test for lead poisoning; b. a mandatory order compelling defendant Sullivan to require use of lead blood level assessments as the screening test for lead poisoning; c. a permanent injunction enjoining the operation and effect of any United States Department of Health and Human Services regulations or guidelines which permit the use of EP tests to test for lead poisoning instead of lead blood level assessment tests; d. a permanent injunction and mandatory order that compels defendant Sullivan to require the States to use lead blood level assessment tests and to test, using lead blood level assessment tests, each Medicaid-eligible child the States have failed to test or have tested with EP tests instead of lead blood level assessment tests; e. an award of attorney’s fees, litigation expenses, costs and such other relief as may be appropriate; and f. such other relief as may be appropriate. Dated: October 21, 1992 Respectfully submitted, Edward B. Cloutman, III Law Office of Edward B. Cloutman, III 3301 Elm Street Dallas, TX 75226 (214) 939-9222 Julius L. Chambers Alice Brown NAACP Legal Defense & Educational Fund, Inc. 99 Hudson Street, Suite 1600 New York, NY 10013 12 (212) 219-1900 Bill Lann Lee Kirsten D. Levingston NAACP Legal Defense & Educational Fund, Inc. 315 West Ninth Street, Suite 208 Los Angeles, CA 90015 (213) 624-2405 Jane Perkins National Health Law Program 1815 H Street, N.W. Suite 705 Washington, DC 20006 (202) 887-5310 Carlene NcNulty North State Legal Services 114 West Corbin Street Hillsborough, N.C. 27278 (919) 732-8137 Lucy Billings Marie-Elena Ruffo Bronx Legal Services 579 Courtlandt Avenue Bronx, N.Y. 10451 (212) 992-6250 iiM'Lan'n Lee Attorneys for 1Plaintiff-Int^rvenors PUEBLO, ABC, NYCCELP and plaintiff-intervenors individual 13 CERTIFICATE OF SERVICE Undersigned counsel for proposed plaintiff-intervenors certifies that copies of the Proposed Complaint in Intervention was served on counsel for the parties by telefacsimile and by United States mail, first class postage prepaid, to: Michael M. Daniel, P.C. 3301 Elm Street Dallas, TX 75226-1637 (214) 939-9229 (telefacsimile) Edwin N. Home Assistant Attorney General General Litigation Division P.O. Box 12548 Capital Station Austin, TX 78711-2548 (512) 447-0511 (telefacsimile) Alina S. Kofsky Sheila Lieber Department of Justice Federal Programs Branch, Civil Division 901 E Street, N.W. Washington, D.C. 20530 (202) 616-8470 (telefacsimile) This 21st day of October, 1992. Levingst NAACP LEGAL DEFENSE AND EDUCATIONAL FUND, INC. July 15, 1992 The Honorable Louis W. Sullivan Secretary United States Department of Health and Human Services 200 Independence Avenue, SW Room 615F Washington, D.C. 20201 Re: Failure by HCFA to Implement CDC Statement on Preventing Lead Poisoning in Young Children Dear Secretary Sullivan: The purpose of this letter is to bring to your attention a significant problem in the implementation by the Health Care Finance Administration (HCFA) of the October 1991 Statement on Preventing Lead Poisoning in Young Children issued by you and the Centers for Disease Control (CDC). The Legal Defense Fund has been monitoring the implementation of the CDC Statement because of the great number of poor African-American children affected by lead poisoning. We request that you instruct HCFA to follow the CDC Statement and discontinue the use of the erythrocyte protoporthyrin (EP) test to screen for lead poisoning. Only the venous blood lead test as dictated by the CDC Statement should be used. Briefly stated, HCFA is in the process of preparing guidelines for State Medicaid program directors that indicate that state programs may continue to use the EP test to screen for lead poisoning. The use of this EP test potentially will leave hundreds o f thousands of children effectively unscreened for lead poisoning. HCFA is recommending the EP test despite the fact that it is not sensitive enough to test for poisoning at the new lower levels established by the CDC According to the CDC, screening should be done using the venous blood lead test. Unless HCFA’s guidance to State Medicaid officials is altered, HCFA will frustrate implementation of the screening that CDC has established as standard medical practice for poor, Medicaid-eligible children, the very group that is at greatest risk of poisoning by lead. A TT A Offuet Suite 301 Viiu* 2T* 1275 K N W .115 Wc*t Nmth Street W aihm gton. D C 2U005 lit* A n«tlo . CA (2021 682-* 300 2t.M *v24-2-»iiv Ccnrr̂/uonj mr MutttbLrf* (7.J. tax eurpesn. The NAACP Legal Defense A Educational Fund. Inc. (LDF) n *»oc part of the National Association (o t Advancem ent o f Colored People (NAACP) although LDF w at founded by the NAACP and d u r* j iu->« L.. L-J r... The Honorable Louis W. Sullivan July 15, 1992 Page 2 AimnM a vear aeo the CDC Statement lowered the level of blood lead sufficient to trigger medical and public deciliter to lO/ig/dL. The reason for towering thê hr«hoId was ma ^ ^ ^ ^ evidence showing that some adverse effe octal comDelling that it must be as 1 0 « W L - f “ “ ^ “ i l d t S iL d exposure." CDC a major force n determm. gabove 10 .fj/dL, frequent rescreening and possib e Statement at • Ued f with greater intervention at progressively " h . t 46. As a result, the CDC Statement declared that. Since erythrocyte protoporphyrin (EP) is not sensitive enough to identify more than a small percentage of children with blood lead levels between 10 and 25 MgML and misses many children with blood lead levels a 25 ug/dL . . . measurement of blood lead levels should replace the EP test as the primary screening method. CDC Statement at 41 (citing, McElvaine MD Orbach HG Binder S. Blantema, LA. MaesEF.KriegRM. ° £ t h e Pediatr (in press)for elevated blood lead levels, Chicago, Illinois, 1988-1989, J. Pemarr p ; l i l l v L id at 2 (’Since the erythrocyte protoporphyrin level is not sensitive enough tof identify children with etovated blood lead levels below about 25 the sheening test of choice is now blood lead measurement.). In the attached draft letter, HCFA h a s t e n directors accurate guidance on the implementation o e Ackjlowledging that major exception. The exception, however, is a gj**1 8 * t a seTlsitive the blood lead test is "the test of choice and ^ “ ^ nevertheless indicator for blood lead levels below 25 fig/dU the HCFA V ' Q blood permits the EP test to be used for screening as an alternative to the venous D^o lead test when verbal assessment indicates absence of high risk. Id. at 2,4, attach chart entitled "EPSDT Lead Screening Requirements. According to the CDC, the problem with continued use of the EP test is that it is ’’not sensitive enough to identify more than a small percentage of children N h h L P L . A . i-1 A G E . 0 0 4 im h levels between 10 and 25 /xg/dL and misses many children with blood leadlevels > 25 us/dL.” (CDC Statement at 41). By permitting continued use of the EP test despite knowledge of its limitations, HCFA purposefully compromi he o l d o a l Sru t oTyour CDC Statement to lower the threshold of lead potsonmg andtoWentify and treat many undiagnosed young chtldren presently suffering from lead poisoning. There are two mitigation measures contained in the HCFA draft, neither of w h l c h ^ r v r , the draft requires that only a Wood J f ^ t bea “ m when verbal assessment estabhshes high risk. However, the CDC statement TOm which the questions set forth in the verbal assessment are derived ̂u" ^ “l -L l a m e n t a U 2 ( m ^ " u t e S r e f e “ " h o s e at or aboCe 35 MS W * . levels at which the EP test is sensitive, not at low levels where it is not sensitive. S C I S S - S K S S ,™time enough for State Medicaid authon te testing which is the only to increasi their capacity to perform v e n o u s b ^ o d l M d tetm g, wm n y reason the Statement contemplates for temporary use of the t r . Statement at 41. t oct the HCFA draft refers to limited state resources. However, the Medicaid-eligible population of young children is not a demographic wtegory a o risk It is a category of poor and minority children who are at high risk and who require the irostf rigor in screening. The CDC Statement is eloquent in its pent that: The Honorable Louis W. Sullivan July 15, 1992 Page 3 i ' i m H <w L_ . H . The Honorable Louis W. Sullivan July 15, 1992 Page 4 Although all children are at risk from lead toxicity, poor and minority children are disproportionately affected. Lead exposure is at once a by-product of poverty and a contributor to the cycle that perpetuates and deepens the state of being poor. CDC Statement at 12. Lead poisoning, unhappily, is a civil rights issue. the us progra.~. ~ ..v ------------- me if I can be of further assistance. Sincerely, Jiilius L. Chambers iiirector-Counsel JLC:sm Attachments cot Assistant Secretary James Mason William Toby, HCFA JCT d.\ i J rr\o,'l INHHLr ' w‘ l'A« ,w tN :I OF HEALTH & HUMAN SERVICES ‘ 4 & ~ ------------------------------------- ------ — — AUG 6 1992 P A 13 E . 0 0 b H ealth Care F inancing A am in is, ra, i(. 632 j Security Boulevard Baltimore, MO 21207y»rr>d Mr. Julius L. Chambers Director-Counsel NAACP Legal D efense and Educational Fund, Inc. 99 Hudson. Street, 'Suite 1600 New York,' N .Y , 1G013-2S97 Dear Mr. Chambers: AUfiioi9ge I am responding to your July 15 letter to Secretary Louis W Snii^r, • S S * I d developed forked screetJgTrough p r ^ f B “* “ d * “* * “ S a ‘ a * ’s> and T r e a n n e m fS ^ ) We appreciate and share your concern that Medicaid eligible children he ^ n e d for leadpofconing and that any health prob ,e t SS t S S S S S B * J?4 1** * f f i o f ^ r u r u o d e r s u o d l n g of the J 5 « - * - ^ m m ^ d s yenoiiS blood tests in afl cases. Our draft indicated that it was the ^ S S S ^ S S ? theSta^ ^ CDCreviscs its ^tement on preventing enntmood poisoning, we would anticipate additional revisions. % C D C r ^ e n d e d blood lead tests, with blood drawn either by capillary or venom •: f̂ tJtOOS. However, there are a number of real impediments to immediately implementing t^iversal blood lead testing, particularly limited public health* laborawr?capB,%.aad the need to incoiporate these new procedures in medical S S L time, CDC and we reeognia that, while currently not the 5 s * 2 rtt& zszrss r e r — • J?-- /•